

Clinical Features of Patients with Morphea and the Pansclerotic Subtype: A Cross-sectional Study from the Morphea in Adults and Children Cohort

Andrew Kim, Nicholas Marinkovich, Rebecca Vasquez, and Heidi T. Jacobe

ABSTRACT. Objective. Pansclerotic morphea is a poorly described form of morphea with little information on prevalence, demographics, and clinical features. Classification criteria for this subtype varies and the distinction from other forms of morphea, such as extensive generalized morphea and pansclerotic morphea, is not always clear. The purpose of our study was to clarify classification criteria for pansclerotic morphea by identifying its prevalence in the morphea in adults and children (MAC) cohort and describing its demographic and clinical features as compared with generalized morphea.

Methods. Patients who met predefined criteria for generalized and pansclerotic morphea were identified using a modified Laxer and Zulian classification system. Baseline demographic and clinical features of the patients were compiled and then analyzed for traits characteristic of pansclerotic morphea versus those of generalized morphea. One hundred and thirteen patients met the criteria for inclusion: pansclerotic (n = 13) and generalized morphea type (n = 100).

Results. Patients with pansclerotic morphea were more frequently male (46.2% vs 6%; p < 0.0001); had a shorter time to diagnosis (mean difference of 10.4 mos; 95% CI: 0.8–19.9 mos; p = 0.0332); higher rates of functional impairment (61.5% vs 16%; p = 0.0046); higher rates of deep involvement (61.5% vs 17%; p = 0.004); and higher average Rodnan Skin Score (mean difference of 10.8 points; 95% CI: 5–16.6; p = 0.0017), Localized Scleroderma Skin Damage Index (mean difference 28.3; 95% CI: 9–47.6; p = 0.009), and Physician Global Assessment of Disease Damage scores (mean difference 25.1; 95% CI: 0.3–50; p = 0.048).

Conclusion. Our results suggest demographic and clinical features are sufficient to define the pansclerotic subtype as they represent a distinct clinical phenotype with a more rapidly progressive and severe course commonly accompanied by disability. Presence of features of the pansclerotic phenotype should alert practitioners to the possibility of significant morbidity and the need for early aggressive treatment. (First Release Dec 1 2013; J Rheumatol 2014;41:106–12; doi:10.3899/jrheum.130029)

Key Indexing Terms:

LOCALIZED SCLERODERMA

MORPHEA

PANSCLEROTIC SCLEROSIS

Morphea, also known as localized systemic sclerosis (SSc), is an inflammatory skin disorder characterized by excessive collagen deposition in the skin, dermis, and/or subcutaneous tissues^{1,2,3,4,5}. Morphea causes permanent cosmetic and

functional sequelae including hyperpigmentary or hypopigmentary changes, tissue atrophy (both superficial and/or deep), or impaired joint mobility or deformity.

At this time, there is no widely accepted classification scheme for morphea. Several have been published, including those of Laxer and Zulian, which includes 5 subtypes: circumscribed (superficial or deep), linear (superficial or deep), generalized, pansclerotic, or mixed (Table 1)³. Another frequently cited alternate system by Peterson, *et al* also designates 5 types, which include plaque, deep, linear, bullous, and generalized with “disabling pansclerotic morphea of children” noted as a subtype of deep morphea⁴. Within these classification systems, the greatest variation is in the description of the pansclerotic subtype, particularly in the depth of tissue involved. Further, the distinction between extensive generalized morphea and pansclerotic morphea is not always clear because the lesion distribution in pansclerotic morphea overlaps with the description of multiple body site involvement in generalized morphea. Some authors such as Tuffanelli categorize pansclerotic morphea as a subset of generalized morphea⁶.

From the Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas; Department of Dermatology, Washington Hospital Center, Washington, DC, USA.

Research for this manuscript was supported in part by US National Institutes of Health (NIH) Grant No. K23AR056303-4. Also supported in part by the UT-STAR, NIH/NCRR/NCATS Grant No. UL1RR024982. The content is solely the responsibility of the authors and does not necessarily represent the official views of UT-STAR, The University of Texas Southwestern Medical Center at Dallas and its affiliated academic and healthcare centers, the National Center for Research Resources, or the NIH.

A. Kim, MD, Department of Dermatology, University of Texas Southwestern Medical Center; N. Marinkovich, MD, Department of Dermatology, Washington Hospital Center; R. Vasquez, MD; H.T. Jacobe, MD, MSCS, Department of Dermatology, University of Texas Southwestern Medical Center.

Address correspondence to Dr. H.T. Jacobe, University of Texas Southwestern Medical Center, Department of Dermatology, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9069, USA. E-mail: heidi.jacobe@utsouthwestern.edu

Accepted for publication August 8, 2013.

Table 1. Preliminary proposed classification of juvenile localized scleroderma. From R. Laxer, F. Zulian. *Curr Opin Rheumatol* 2006;18:606-13; with permission.

Main Group	Subtype	Description
(1) Circumscribed morphea	(a) Superficial	Oval or round circumscribed areas of induration limited to epidermis and dermis, often with altered pigmentation and violaceous, erythematous halo (lilac ring). They can be single or multiple
	(b) Deep	Oval or round circumscribed deep induration of the skin involving subcutaneous tissue extending to fascia and may involve underlying muscle. The lesions can be single or multiple. Sometimes the primary site of involvement is in the subcutaneous tissue without involvement of the skin
(2) Linear scleroderma	(a) Trunk/limbs	Linear induration involving dermis, subcutaneous tissue and, sometimes, muscle and underlying bone and affecting the limbs and the trunk
	(b) Head	<i>En coup de sabre</i> (ECDS). Linear induration that affects the face and the scalp and sometimes involves muscle and underlying bone Parry Romberg or progressive hemifacial atrophy loss of tissue on one side of the face that may involve dermis, subcutaneous tissue, muscle and bone. The skin is mobile
(3) Generalized morphea		Induration of the skin starting as individual plaques (four or more and larger than 3 cm) that become confluent and involve at least 2 out of 7 anatomic sites (head-neck, right upper extremity, left upper extremity, right lower extremity, left lower extremity, anterior trunk, posterior trunk)
(4) Pansclerotic morphea*		Circumferential involvement of limb(s) affecting the skin, subcutaneous tissue, muscle and bone. The lesion may also involve other areas of the body without internal organs involvement
(5) Mixed morphea		Combination of 2 or more of the previous subtypes. The order of the concomitant subtypes, specified in brackets, will follow their predominant representation in the individual patient [i.e., mixed morphea (linear-circumscribed)]

* MAC registry classification based on the following clinical description: circumferential involvement of majority of body surface areas with sparing of fingers and toes; affecting the dermis and frequently subcutaneous tissue, muscle, and/or bone; no internal organ involvement. MAC: Morphea in Adults and Children.

The largest case series to date describes 14 children with pansclerotic morphea characterized by extensive body surface area (BSA) involvement, often circumferential in nature, and deep tissue involvement⁷. Lesions were noted to spare only the fingers and toes. A number of case reports, predominantly involving children, detail similar clinical findings; however, the definition and frequency of deep tissue involvement was ambiguous and inconsistent^{8,9,10}. Further, the relative frequency among morphea patients, demographic features, clinical features, and response to treatment of pansclerotic morphea remains unknown, especially among adults.

The Morphea in Adults and Children (MAC) cohort is designed to assess the clinical, demographic, and autoimmune features of carefully phenotyped morphea patients. As a prospective cohort study, it is ideally situated to report the prevalence and clinical characteristics of patients with pansclerotic morphea including the nature and frequency of deep involvement.

We have observed several patients with morphea who have skin lesions consistent with the clinical description for pansclerotic morphea. However, none have demonstrable bony involvement. These observations along with the ambiguity in the literature led us to hypothesize that despite meeting criteria for generalized morphea based on number of body sites involved, pansclerotic morphea is clinically

distinct. Thus, we identified patients with pansclerotic morphea within the MAC cohort using a modified Laxer and Zulian classification scheme (based on consistent clinical features and free from the requirement of deep involvement) and described the demographic and clinical features of this subtype to better distinguish it from generalized morphea.

MATERIALS AND METHODS

This is a cross-sectional study of patients in the MAC cohort meeting predefined criteria for pansclerotic morphea and generalized morphea.

Patients. All study patients were drawn from the MAC cohort: an ongoing prospective registry established in 2007 at the University of Texas Southwestern Medical Center, to better understand the demographic, clinical, and autoimmune features of morphea. The registry enrolls patients 3 years of age or older demonstrating clinical and/or histological features of morphea. Participants were recruited from within the University of Texas Southwestern Medical Center system, encompassing 2 dedicated pediatric care facilities, a county hospital, and a faculty-based practice. Additionally, patients were enrolled through regional and national referrals from private practitioners (both pediatric and adult rheumatologists and dermatologists) in an attempt to enroll patients of widely varied disease severity, socioeconomic, and demographic backgrounds.

All patients enrolled in the registry were examined by HJ (who has expertise in morphea), assigned subtypes modeled after a modified version of the Laxer and Zulian classification system as noted in Table 1, and given clinical scores. Pansclerotic morphea was defined as the presence of a cutaneous distribution pattern consistent with prior reports of near total BSA involvement, with the characteristic sparing of the fingers and toes.

Additional criteria of deep involvement beyond the dermis was not factored into the categorization of patients because of the significant variation in both definition and lack of consistent reporting of deep involvement per prior reports^{2,3,7,10,11,12,13}. Registry participants completed a comprehensive health questionnaire, in addition to the collection of blood and/or skin biopsy samples for immunologic and genetic studies. Patient-reported findings were confirmed by interview, physical examination, and/or requisition of their medical records. Inclusion criteria for our study consisted of any patient having 1 or more registry visits with the designation of either pansclerotic or generalized morphea. Clinical data and biological samples were obtained from patients at each annual followup study visit when available for longitudinal analysis.

Variables of interest. Clinical and demographic information was extracted from case report forms (designed specifically for the MAC cohort) administered at the initial enrollment visit. Clinical measures used to assess disease severity included an assessment of functional impairment (defined as presence of limited range of motion, contractures, and/or joint deformity due to direct morphea involvement as determined by physical examination by HJ) and deep involvement beyond the dermis [determined by clinicopathological diagnosis and/or magnetic resonance imaging (MRI)]. Depth of involvement was assessed primarily by the location of inflammatory cell infiltrate and depth of sclerosis in conjunction with other signs, such as thickening or homogenization of collagen bundles as well as compression or loss of appendageal structures. MRI was used to assess for subcutaneous septal thickening, fascial thickening, perifascial enhancement, myositis, or enhancement of the bone to aid in lesion depth determination. Any reported systemic symptoms or concomitant disorders were verified by history, direct examination, or review of medical records. Systemic symptoms reported in our study were established by referral to appropriate care providers for evaluation and treatment.

The Dermatology Life Quality Index (DLQI) was used to assess the effect of morphea on quality of life. Standardized clinical scoring systems included both the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) and the Modified Rodnan Skin Score (mRSS)^{14,15}. The mRSS was used concurrently because the LoSCAT was not available at the inception of the cohort study and thus was continued to provide continuity for patients enrolled prior to the implementation of the LoSCAT. The LoSCAT assesses activity and damage through the components of Localized Scleroderma Skin Activity Index (LoSAI), Physician Global Assessment of Disease Activity (PGA-A), Localized Scleroderma Skin Damage Index (LoSDI), and Physician Global Assessment of Disease Activity (PGA-A). These activity and damage indices have been validated for use in morphea and have shown substantial to excellent interrater and intrarater reliability, with the damage components showing little variation in stable patients over a 3-month period^{15,16,17}.

Autoantibody testing for antinuclear antibodies (ANA) and antihistone antibodies¹⁸ was performed with sera isolated from whole blood. ANA for all subjects were obtained in a single laboratory by a single investigator (FA) and were analyzed using indirect immunofluorescence (IIF) on HEp-2 cells (Antibodies Inc.) by previously published methods¹⁹. Titers $\geq 1:80$ were considered positive and IIF patterns of either speckled, centromere, nucleolar, homogenous, or mitochondrial were designated by FA. Antihistone antibody (AHA) testing was determined in a single laboratory (HJ) using ELISA kits (Orgentec Diagnostika) according to the manufacturer's directions, with levels > 40 U/ml considered positive, as determined by the manufacturer.

Additional data collected on patients with pansclerotic morphea included systemic immunosuppressive treatments administered after enrollment in the registry, as well as any occurrence of systemic symptoms and related complications.

Statistics. Means or medians along with the SD were calculated for continuous variables. Total count and percentages were calculated for categorical variables. We compared demographic and clinical features of generalized patients with and without the pansclerotic subtype using the

Student t test for continuous variables and a 2-tailed Fisher exact test for categorical variables. P values ≤ 0.05 were considered significant. Statistical analysis was performed using GraphPad Prism software, version 5.04.

RESULTS

Study patients. Of the 360 patients enrolled in the MAC cohort between September 2007 and August 2012, 113 were identified with having either pansclerotic or generalized morphea at enrollment, with 13 patients meeting predefined criteria for the pansclerotic type and 100 for the generalized type.

Baseline patient demographics and clinical characteristics for all patients are summarized in Table 2, with further reporting broken down by subtypes. Overall, patients had a mean age at enrollment of 53 years and were predominantly white and female.

Overall clinical characteristics of study patients. White (76.1%) females (89.4%) comprised the majority of patients in the group. Only 12 (10.6%) had lesion onset at ≤ 18 years of age. Twenty-one percent had functional impairment and 22.1% had evidence of deep involvement. LoSCAT scores for patients of the generalized morphea subtype were as follows: means for the LoSDI, Physician Global Assessment of Disease Damage (PGA-D), LoSAI, and PGA-A were 23.9, 30.7, 30.6, and 54.3, respectively. A mean number of 2.4 prior and/or current treatments were reported. Topical corticosteroids were the most frequently used therapy at enrollment, with 69.9% reporting use, followed by phototherapy and methotrexate (MTX) at 24.8% and 23%, respectively. ANA testing was available for 59 patients, 18 of whom had positive ANA titers. A speckled pattern predominated in 72.2% of cases (13/18). Similarly, sera from 91 patients underwent AHA testing, 7 of whom were positive. The most common concomitant autoimmune disorders among all generalized morphea patients were rheumatoid arthritis (n = 6), genital lichen sclerosis et atrophicus (n = 5), and psoriasis (n = 4). None of the patients had sclerodactyly, Raynaud phenomenon, or nailfold capillary changes consistent with SSc. Skin biopsies were performed on nearly all study patients (12/13 pansclerotic patients and 92/100 generalized patients), but few had deep incisional biopsies (3/13 pansclerotic patients, 1/100 generalized patients) or MRI studies (4/13 pansclerotic patients, 1/100 generalized patients) performed at initial presentation.

Pansclerotic subtype. Of all patients in the MAC cohort, 3.6% had pansclerotic morphea. The characteristics of patients with the pansclerotic subtype compared to patients with generalized morphea are presented in Table 2. Compared to patients with generalized morphea, those of the pansclerotic subtype were more predominantly male (46.2% vs 6%; $p < 0.0001$), had shorter time to diagnosis (median time of 6 vs 10 months; $p < 0.0332$), higher rates of functional impairment (61.5% vs 16%; $p = 0.0046$), higher rates of deep involvement as defined by skin biopsy (61.5%

Table 2. Study patient characteristics.

	All Patients	Pansclerotic	Generalized	p
Total no. patients	113	13	100	
Age, yrs, mean (SD)	53 (17)	54 (21)	53 (16)	0.848
Age onset, yrs, mean (SD)	49 (19)	53 (22)	48 (18)	0.447
Time to diagnosis, mos, median (SD)	9 (29)	6 (13)	10 (30)	0.0332*
Sex, n (%)				< 0.0001*
Male	12 (10.6)	6 (46.2)	6 (6)	
Female	101 (89.4)	7 (53.8)	94 (94)	
Race, n (%)				
White	86 (76.1)	7 (53.8)	79 (79)	0.145
Latino	16 (14.2)	4 (30.8)	12 (12)	0.087
African American	6 (5.3)	2 (15.4)	4 (4)	0.141
Asian	3 (2.7)	0 (0)	3 (3)	1.000
Other	2 (1.8)	0 (0)	2 (2)	1.000
Functional impairment, n (%)	24 (21.2)	8 (61.5)	16 (16)	0.005*
Deep involvement, n (%)	25 (22.1)	8 (61.5)	17 (17)	0.004*
Number of treatments, n (SD)	2.4 (2)	2.8 (2)	2.3 (2)	0.175
mRSS, mean (SD)	8 (6)	18 (9)	7 (4)	0.002*
DLQI, mean (SD)	7 (6)	12 (8)	6 (6)	0.056
LoSAI, mean (SD)	31 (27)	54 (40)	27 (22)	0.065
LoSDI, mean (SD)	24 (19)	48 (26)	20 (14)	0.009*
PGA-A, mean (SD)	54 (29)	64 (30)	53 (29)	0.308
PGA-D, mean (SD)	31 (23)	52 (34)	27 (19)	0.048*

* Statistically significant ($p < 0.05$). DLQI: Dermatology Life Quality Index; LoSAI: Localized Scleroderma Skin Activity Index; LoSDI: Localized Scleroderma Skin Damage Index; mRSS: modified Rodnan Skin Score; PGA-A: Physician Global Assessment of Disease Activity; PGA-D: Physician Global Assessment of Disease Damage.

vs 17%; $p = 0.004$), higher average mRSS (mean of 17.8 vs 7; $p = 0.0017$), higher LoSDI score (mean of 48 vs 19.7; $p = 0.009$), and higher PGA-D score (mean of 52 vs 26.9; $p = 0.048$). No significant differences were found in visit age, onset age, race, number of treatments received, DLQI score, or disease activity scores. The most common treatments reported by patients with pansclerotic morphea were systemic corticosteroids, MTX, and topical steroids at rates of 61.5%, 53.8%, and 38.5%, respectively.

Autoantibody testing results were similar between both groups; ANA were present in 28.6% (2/7) in the pansclerotic group versus 30.8% (16/52) in the generalized group. AHA were correspondingly present in 10% (1/10) and 7.4% (6/81) of patients with pansclerotic and generalized morphea. Treatments prescribed at baseline and other concomitant systemic features, such as dysphagia and/or restrictive pulmonary defects for the pansclerotic patients, are reported in Table 3. Patients with restrictive defect on

Table 3. Prescribed treatments and systemic features of the pansclerotic morphea patients.

Patient	Treatment	Systemic Features
1	MTX, UVA-1	
2	MTX	
3	UVA-1	
4	Prednisone, UVA-1	Edema of hands and fingers, dysphagia, restrictive-pattern PFT, chronic ulcers, fingertip necrosis, flexural fissures
5	MTX, prednisone, UVA-1	Edema of hands and fingers
6	MTX, prednisone	Restrictive-pattern PFT, SCC*, BCC, flexural fissures
7	MTX, prednisone	Restrictive-pattern PFT (oxygen dependent), ITP, dysphagia, SCC*, BCC, flexural fissures
8	MTX, prednisone	
9	MTX, prednisone	
10	MTX, prednisone	
11	MTX, prednisone	
12	MTX, prednisone	
13	None	

* History of SCC prior to initial development of morphea lesions. BCC: basal cell cancer; ITP: idiopathic thrombocytopenic purpura; MTX: methotrexate; PFT: pulmonary function tests; SCC: squamous cell cancer; UVA-1: ultraviolet light A-1.

pulmonary function test had followup computed tomography (CT) scans, with none demonstrating parenchymal lung disease. The restrictive defect was attributed to circumferential involvement of the chest in all cases. Evaluation of patients with dysphagia revealed an absence of esophageal dysmotility. Rather, all defects were secondary to extensive sclerotic neck lesions or abdominal sclerosis. Those with hand edema had circumferential full thickness sclerosis of the forearm, in one case causing necrosis of the fingertips and autoamputation in the absence of direct involvement of morphea in the fingertips. Evaluation by hand surgery and vascular surgery revealed absence of intrinsic vascular disease, instead implicating the symptoms as a result of compartment syndrome due to extensive sclerosis of the forearm. Two patients had squamous cell carcinoma (SCC) and basal cell carcinoma.

In addition, the traditional evolution of lesions among the patients of the pansclerotic type was described as beginning on the trunk with subsequent rapid centrifugal spread. Abrupt cutoff at the metacarpophalangeal or metatarsophalangeal joints was observed on examination of this series of patients (Figure 1). In contrast, patients with generalized morphea developed individual lesions that gradually proliferated over time and coalesced.

Longitudinal data for 4 patients of the pansclerotic subtype was available through the third annual followup. The dynamic changes in the mean DLQI, mRSS, LoSAI, LoSDI, PGA-A, and PGA-D among these 4 patients are presented in Figure 2, which revealed a gradual decrease in disease activity over time, but persistent damage related to the initial skin lesions.

DISCUSSION

This cross-sectional assessment of patients with generalized morphea in the MAC cohort characterized demographic and clinical features of patients to identify unique attributes

within this group. Our results indicate that pansclerotic morphea represents 3.6% of morphea cases in our cohort and is characterized by a more rapidly progressive and severe phenotype than generalized morphea with features distinct from SSc. While prevalence in this cohort may not be representative of the overall morphea population, the results nonetheless support the clinical utility of identifying pansclerotic patients as a unique phenotype for the purposes of evaluation and treatment.

The results of our study confirm prior observations in which patients with pansclerotic morphea have a more severe clinical course with a higher relative frequency of males as compared with other morphea patients^{7,8,9,10,11,12,13}. The unique distribution of skin lesions in our case series was also consistent with prior reports of centrifugal spread encompassing near total body involvement except for the digits. Reports in the literature also rarely note early lesions initially mimicking other morphea types such as linear morphea⁷. Nonetheless, the pattern observed in our cohort and the one most frequently reported in the literature is distinct from both the cutaneous manifestations reported for SSc, which typically begins with acrosclerosis, and generalized morphea, which tends to begin with individual plaques. A high frequency of deep tissue involvement, which has historically been noted as one of the defining features, was also observed in this cohort of patients of the pansclerotic subtype, even though it was not a defining factor.

Prior reports indicate patients with pansclerotic morphea are at an increased risk for SCC. We observed 2 patients in the pansclerotic group who had SCC, but both were over 60 years of age with fair skin, and both already had a history of SCC preceding the onset of morphea. This picture is further complicated by the use of immunosuppressive agents in both cases, which are also known to increase the risk of SCC²⁰. The literature suggests a more delayed onset of SCC



Figure 1. Pansclerotic morphea showing extensive body surface area involvement (A) with distinct lesion features such as abrupt cutoff at the metacarpophalangeal joints (B, C).




Figure 2. Longitudinal analysis of average clinical score measures of 4 pansclerotic patients with followup through Year 3.

in the range of 7 to 12 years after the development of morphea^{11,21} that is not yet captured by the shorter followup times currently on record for our patients. Therefore, conclusions regarding risk of SCC are difficult to determine.

One novel observation in our cohort is the adult-predominant composition, whereas most reported cases are of disease onset in childhood^{1,4,7,8,9,10,22}. The age distribution of patients in the study is not the result of preferential enrollment in the MAC cohort, which is composed of 97 children and 263 adults. One explanation for this discrepancy could be a publication bias, because these reports are not the result of a prospective study of morphea overall, but rather involve a retrospective report of only the most severe cases that are most likely to be published in the literature. Children with pansclerotic morphea likely have the more severe symptoms and complications from impaired growth, compared with adults. Alternatively, pansclerotic morphea in children may entail a different clinical course and/or more severe disease pattern than those found in adults.

While our patients had clinical findings similar to SSc, these were secondary to cutaneous manifestations of morphea rather than direct internal organ involvement. Sclerodactyly-like changes were caused by edema of the hands and fingers due to circumferential sclerosis of the upper extremities. Severe circumferential sclerosis of the forearm causing vascular compromise of the fingers led to digital necrosis, as was previously suggested in the report by Maragh, *et al*¹¹. Restrictive pulmonary function test patterns were attributed to external restrictive mobility of the rib cage, because followup CT scans did not reveal pulmonary parenchymal changes. Dysphagia only occurred with severe circumferential sclerosis of the neck, without evidence of esophageal dysmotility. Further, characteristic findings of SSc were absent (including sclerodactyly, Raynaud phenomenon, and nailfold capillary changes)²³. In addition,

the distribution pattern for SSc has a tendency to spread proximally from the distal extremities, whereas pansclerotic lesions more frequently show the reverse pattern, with proximal lesions spreading distally.

Longitudinal analysis was performed for 4 patients with sufficient followup. These results showed high measures for activity with high LoSAI and PGA-A scores that quickly resolved after initiation of treatment, accompanied by a concomitant rise in the damage measures, LoSDI and PGA-D, from baseline. These results seem to suggest some patients respond to aggressive treatment. On the other hand, 1 of 13 patients in this report passed away secondary to complications stemming from her morphea 3 years after disease onset despite aggressive treatment (Table 3). This compares to 4 deaths out of the remaining 343 patients in the whole registry (all were unrelated to morphea or its treatment). This confirms prior reports of poor longterm survival (< 10 years). However, future analysis of the cohort with longer followup will be needed to confirm these initial observations.

Historical descriptions of pansclerotic morphea have consistently defined it by a unique general distribution pattern with associated deep involvement^{1,2,3,4,5,6,7,8,9,10,11,12,13,22}. Unfortunately, they have not been consistent in how depth of involvement is either defined (ranging from deep dermal to bone) or determined^{2,3,7,10,11,12,13}. We removed this criterion because of ambiguity and instead solely assigned the pansclerotic subtype based on the clinical criterion of rapid evolution of near total BSA involvement typically spreading centrifugally, sparing the fingers and toes. To make the designation of deep involvement, we required either histopathologic or MRI evidence of involvement below the dermis. While skin biopsies were performed on nearly all study patients, few were of the deep incisional type (because of problems with wound healing) and only a very small minority had MRI performed. Thus, sampling error is possible because these methods could miss or may

not identify fascial, muscle, or bone lesions. This may partially account for the lower rate of deep tissue involvement in our study compared to previous ones. However, our results suggest that patients with pansclerotic morphea are clinically distinct in terms of demographics, disease course, and morbidity. Therefore, confirmation of deep tissue involvement, while commonly present, is not necessary for diagnosis. In fact, it may unnecessarily relegate patients with severe disease into the generalized or other subtype that is frequently treated less aggressively²⁴. It is important to highlight, though, that deep involvement of tissue below the dermis is a prominent feature in pansclerotic morphea, contributing to the high rate of functional disability in this subtype.

Limitations of our study include those inherent to cross-sectional studies, potential selection bias, and the limited numbers of subjects available for analysis. Limitations due to limited numbers are inherent in studying a rare disease that restricts the types of analysis that can be performed. Selection bias of patients in our registry may be evidenced by an adult-predominant age distribution seen in our series compared to the children-predominant prior reports. This may reflect the adult-focused practice at the study site. Additionally, as a tertiary referral center, our morphea registry cohort may not be an accurate reflection of the overall general morphea population because of an overrepresentation of the most severe types seen at this center. This factor may help explain the higher rates of some of the more severe types of morphea noted in our registry.

The practical clinical implications for identifying patients with the pansclerotic subtype based on these unique features pertain to the severe and rapidly progressing nature of this particular variant. It warrants distinction from generalized morphea and other morphea subtypes. When pansclerotic morphea is either present or clinically suspected, care providers should be especially vigilant. Patients should be closely followed, with a low threshold for initiating aggressive treatment with systemic immunosuppressives and referrals to relevant specialists for management of the secondary systemic symptoms common in this subtype.

ACKNOWLEDGMENT

We acknowledge Frank Arnett for his contribution in conducting auto-antibody testing for antinuclear antibodies.

REFERENCES

- Zulian F, Athreya BH, Laxer R, Nelson AM, Feitosa de Oliveira SK, Punaro MG, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. *Rheumatology* 2006;45:614-20.
- Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. *J Am Acad Dermatol* 2011;64:217-28.
- Laxer RM, Zulian F. Localized scleroderma. *Curr Opin Rheumatol* 2006;18:606-13.
- Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). *Mayo Clin Proc* 1995;70:1068-76.
- Zulian F. Scleroderma in children. *Pediatr Clin North Am* 2005;52:521-45.
- Tuffanelli DL. Localized scleroderma. *Semin Cutan Med Surg* 1998;17:27-33.
- Diaz-Perez JL, Connolly SM, Winkelmann RK. Disabling pansclerotic morphea of children. *Arch Dermatol* 1980;116:169-73.
- Doede T, Wollina U, Hindermann W, Schier F, Bondartschuk M. Pansclerotic morphea in childhood: a case report. *Pediatr Surg Int* 2003;19:406-8.
- Wollina U, Looks A, Uhlemann C, Wollina K. Pansclerotic morphea of childhood-follow-up over 6 years. *Pediatr Dermatol* 1999;16:245-7.
- Tekin NS, Altinyazar HC, Tekin IO, Keskin SI, Kucukoglu R, Onsun N. Disabling pansclerotic morphea: a case report. *Int J Clinic Pract* 2010;64:99-101.
- Maragh SH, Davis MD, Bruce AJ, Nelson AM. Disabling pansclerotic morphea: clinical presentation in two adults. *J Am Acad Dermatol* 2005;53:S115-9.
- Sherber NS, Boin F, Hummers LK, Wigley FM. The "tank top sign": a unique pattern of skin fibrosis seen in pansclerotic morphea. *Ann Rheum Dis* 2009;68:1511-2.
- Song P, Gocke C, Wigley FM, Boin F. Resolution of pansclerotic morphea after treatment with antithymocyte globulin. *Nat Rev Rheumatol* 2009;5:513-6.
- Furst DE, Clements PJ, Steen VD, Medsger TA Jr., Masi AT, D'Angelo WA, et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. *J Rheumatol* 1998;25:84-8.
- Arkachaisri T, Vilaiyuk S, Torok KS, Medsger TA Jr. Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study. *Rheumatology* 2010;49:373-81.
- Arkachaisri T, Pino S. Localized scleroderma severity index and global assessments: a pilot study of outcome instruments. *J Rheumatol* 2008;35:650-7.
- Arkachaisri T, Vilaiyuk S, Li S, O'Neil KM, Pope E, Higgins GC, et al. The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. *J Rheumatol* 2009;36:2819-29.
- Rook AH, Freundlich B, Jegasothy BV, Perez MI, Barr WG, Jimenez SA, et al. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. *Arch Dermatol* 1992;128:337-46.
- Arora-Singh RK, Assassi S, del Junco DJ, Arnett FC, Perry M, Irfan U, et al. Autoimmune diseases and autoantibodies in the first degree relatives of patients with systemic sclerosis. *J Autoimmun* 2010;35:52-7.
- Rangwala S, Tsai KY. Roles of the immune system in skin cancer. *Br J Dermatol* 2011;165:953-65.
- Wollina U, Buslau M, Heinig B, Petrov I, Unger E, Kyriopoulou E, et al. Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma. *Int J Low Extrem Wounds* 2007;6:291-8.
- Wollina U, Buslau M, Petrov I, Pramatarov K. Disabling pansclerotic morphea of childhood. *Expert Rev Dermatol* 2007;2:775-84.
- Matucci-Cerinic M, Allanore Y, Czirjak L, Tyndall A, Muller-Ladner U, Denton C, et al. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. *Ann Rheum Dis* 2009;68:1377-80.
- Johnson W, Jacobe H. Morphea in adults and children cohort II: patients with morphea experience delay in diagnosis and large variation in treatment. *J Am Acad Dermatol* 2012;67:881-9.